Key result
Higher galectin-3 levels in kidney disease independently predict increased mortality and cardiovascular events.
Cohort (n=3,747)
Yes
Answers are grounded in this paper and cite their sources.
Cohort analysis shows elevated galectin-3 predicts cardiovascular events, fatal infections, and mortality in renal impairment, highlighting its prognostic value.
Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of ≥90 ml/min per 1.73 m(2), 60-89 ml/min per 1.73 m(2), and <60 ml/min per 1.73 m(2). We correlated galectin-3 concentrations with demographic, clinical, and biochemical parameters. The association of galectin-3 with clinical end points was assessed by Cox proportional hazards regression within 10 years (LURIC) or 4 years (4D) of follow-up. Mean±SD galectin-3 concentrations were 12.8±4.0 ng/ml (eGFR≥90 ml/min per 1.73 m(2)), 15.6±5.4 ng/ml (eGFR 60-89 ml/min per 1.73 m(2)), 23.1±9.9 ng/ml (eGFR<60 ml/min per 1.73 m(2)), and 54.1±19.6 ng/ml (dialysis patients of the 4D study). Galectin-3 concentration was significantly associated with clinical end points in participants with impaired kidney function, but not in participants with normal kidney function. Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortality, cardiovascular mortality, and fatal infection increased significantly. In dialysis patients, galectin-3 was associated with the combined end point of cardiovascular events. In conclusion, galectin-3 concentrations increased with progressive renal impairment and independently associated with cardiovascular end points, infections, and all-cause death in patients with impaired renal function.
No takes yet. Share an insight, caveat, or question.
Drechsler et al. (2015) conducted a cohort in Impaired renal function, type 2 diabetes, and coronary artery disease (n=3,747). Elevated galectin-3 concentration vs. Lower galectin-3 concentrations / normal renal function was evaluated on All-cause mortality, cardiovascular mortality, and fatal infection (LURIC); combined endpoint of cardiovascular events (4D). Galectin-3 concentrations increased from 12.8 ng/ml in normal eGFR to 54.1 ng/ml in dialysis patients, and higher levels independently predicted mortality and cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: